1. Market Research
  2. > Healthcare
  3. > Diagnostics Market Trends
  4. > Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), & by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends & Forecasts to 2019

The global companion diagnostics market is expected to grow at a CAGR of 22.7% from 2014 to 2019. Factors such as rising need for personalized medicine in cancer treatment, growing adoption of companion diagnostics by the pharmaceutical industry, support from regulatory authorities, and emerging technologies such as next-generation sequencing (NGS) are expected to boost the global companion diagnostics market.
Among technologies, PCR is the most preferred test in the companion diagnostics market, which accounted for a share of 65.5% in 2014. This large share can be attributed to its ease of use, better results, faster turnaround time, and cost-effective solutions. The companion diagnostics market is expected to gain a larger market share in neurology and new oncology applications (leukemia, prostate cancer, and ovarian cancer) due to its efficient detection of biomarkers. Moreover, with the advancement in the bioinformatics field, NGS-based tests have the capability to target multiple genomes simultaneously and are likely to take over the existing technologies in the companion diagnostics market. The need for personalized medicine is increasing and it has gained importance in the research and medical centers, hospitals, and CROs. In the coming years, Asia is expected to be the key growth area in this market.

However, growth of this market is hampered by the non-validated home brew tests that account for a large market share due to its low costs and minimal approval procedures. Moreover, uncertain reimbursement and coverage policies restrict the growth of the global companion diagnostic market, thus limiting the commercialization process.

Reasons to Buy the Report

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms garner a greater market share. Firms purchasing the report can use any one or a combination of the below mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on product portfolios of the top players in the companion diagnostics market. The report analyzes the companion diagnostics market by technology, application, end-user, and geography
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and new product launches in the companion diagnostics market
• Competitive Assessment: In-depth assessment of the market strategies, geographical and business segments, and product portfolios of the leading players in the companion diagnostics market
• Market Development: Comprehensive information about the emerging markets. The report analyzes the market for various companion diagnostics tests/kits across geographies
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the companion diagnostics market

Table Of Contents

Companion Diagnostics Market byTechnology (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry), Application (Breast, Lung cancer), and by End-user (Pharmaceutical Companies, Reference Lab)] - Global Trends and Forecasts to 2019
1 INTRODUCTION 14

1.1 OBJECTIVES OF THE STUDY 14
1.2 MARKETS COVERED 14
1.3 STAKEHOLDERS 15
1.4 MARKET SCOPE 15

2 RESEARCH METHODOLOGY 17

2.1 MARKET SIZE ESTIMATION 18
2.2 MARKET CRACKDOWN AND DATA TRIANGULATION 21
2.3 MARKET SHARE ESTIMATION 21
2.3.1 KEY DATA TAKEN FROM SECONDARY SOURCES 21
2.3.2 KEY DATA FROM PRIMARY SOURCES 22
2.3.3 KEY INDUSTRY INSIGHTS 22
2.3.4 ASSUMPTIONS 23

3 EXECUTIVE SUMMARY 24

4 PREMIUM INSIGHTS 27

5 MARKET OVERVIEW 31

5.1 INTRODUCTION 32
5.2 EVOLUTION 32
5.3 MARKET SEGMENTATION 33
5.3.1 COMPANION DIAGNOSTICS MARKET 33
5.4 MARKET DYNAMICS 34
5.4.1 MARKET DRIVERS 35
5.4.1.1 Regulatory bodies encouraging implementation of companion diagnostics 35
5.4.1.2 Rising demand for targeted cancer treatment and tailored drugs ensure robust market growth in companion diagnostic tests 35
5.4.1.3 Growing adoption of companion diagnostics by pharmaceutical companies and reference laboratories to boost the market 36
5.4.2 MARKET RESTRAINTS 37
5.4.2.1 Reimbursement scenarios in different regions hamper the companion diagnostics market growth 37
5.4.2.2 Laboratory developed tests (home brew tests) affect adoption of companion diagnostic tests 37
5.4.3 MARKET OPPORTUNITIES 38
5.4.3.1 Emerging technologies such as next-generation sequencing (NGS) likely to stimulate the companion diagnostics market 38
5.4.3.2 Increasing scope for companion diagnostics in other cancer indications (ovarian, leukemia, prostate) and neurology 39

6 INDUSTRY TRENDS 41

6.1 PORTER'S FIVE FORCES ANALYSIS 41
6.1.1 THREAT FROM NEW ENTRANTS 41
6.1.2 THREAT FROM SUBSTITUTES 42
6.1.3 BARGAINING POWER OF SUPPLIERS 42
6.1.4 BARGAINING POWER OF BUYERS 42
6.1.5 INTENSITY OF COMPETITIVE RIVALRY 42
6.2 STRATEGIC BENCHMARKING 43
6.2.1 TECHNOLOGY INTEGRATION and PRODUCT ENHANCEMENT 43

7 GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATIONS 44

7.1 INTRODUCTION 45
7.2 BREAST CANCER 47
7.3 LUNG CANCER 48
7.4 COLORECTAL CANCER 49
7.5 MELANOMA 50
7.6 GASTRIC CANCER 51
7.7 OTHER INDICATIONS (PROSTATE CANCER, OVARIAN CANCER, LEUKEMIA, NEUROLOGICAL, AND INFECTIOUS DISEASES) 51

8 GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY 53

8.1 INTRODUCTION 54
8.2 POLYMERASE CHAIN REACTION (PCR) 54
8.3 IN-SITU HYBRIDIZATION (ISH) 55
8.4 IMMUNOHISTOCHEMISTRY (IHC) 56
8.5 OTHER TECHNOLOGIES (NGS,MULTIPLEX ASSAY, and MAB) 58

9 GLOBAL COMPANION DIAGNOSTICS MARKET, BY END USER 59

9.1 INTRODUCTION 60
9.2 PHARMACEUTICAL COMPANIES 61
9.2.1 ACCURATE IDENTIFICATION and RECRUITMENT OF PARTICIPANTS IN CLINICAL TRIALS 61
9.2.2 PHARMACEUTICAL COMPANIES UNDERWENT PARTNERSHIPS and COLLABORATIONS WITH COMPANION DIAGNOSTICS MANUFACTURERS 62
9.2.3 BREAST CANCER and NON-SMALL CELL LUNG CANCER (NSCLC) THE MAJOR FOCUS AREAS FOR PHARMACEUTICAL COMPANIES 62
9.3 REFERENCE LAB 64
9.3.1 IMPORTANCE OF REFERENCE LABORATORIES IN GLOBAL COMPANION DIAGNOSTICS MARKET 64
9.4 OTHER END-USERS (CRO, PHYSICIANS, HOSPITALS and ACADEMIC MEDICAL CENTERS) 66

10 GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY 68

10.1 INTRODUCTION 69
10.2 NORTH AMERICA 70
10.2.1 KEY PLAYERS FOCUSING ON COMPANION DIAGNOSTICS FOR BREAST AND LUNG CANCER 72
10.2.2 FDA INITIATIVES IN THE U.S. TO ENCOURAGE SIGNIFICANT ADOPTION OF COMPANION DIAGNOSTICS 73
10.2.3 ADOPTION OF PAY-FOR-PERFORMANCE PROGRAM STIMULATES PAYORS TO REIMBURSE FOR COMPANION DIAGNOSTIC TESTS 73
10.2.4 FOCUS ON PERSONALIZED MEDICINE IS A MAJOR DRIVER FOR COMPANION DIAGNOSTICS 73
10.3 EUROPE 78
10.3.1 EMA SUPPORTS THE DEVELOPMENT OF COMPANION DIAGNOSTIC TESTS 80
10.3.2 RISING INCIDENCE OF BREAST CANCER IN EUROPE 81
10.3.3 FRAGMENTED REIMBURSEMENT POLICY IN EUROPE HINDERING IN VITRO DIAGNOSTIC MANUFACTURERS FROM INVESTING IN COMPANION DIAGNOSTIC TESTS 81
10.4 ASIA 86
10.4.1 REGULATORY and REIMBURSEMENT FACTORS AFFECT PENETRATION OF COMPANION DIAGNOSTICS IN ASIA 87
10.5 REST OF THE W0RLD 92

11 COMPETITIVE LANDSCAPE 98

11.1 OVERVIEW 98
11.2 MARKET SHARE ANALYSIS, GLOBAL COMPANION DIAGNOSTICS MARKET 99
11.3 AGREEMENTS, PARTNERSHIPS and COLLABORATIONS 102
11.4 MERGER AND ACQUISITIONS 103
11.5 NEW PRODUCT LAUNCHES 104
11.6 EXPANSION 105

12 COMPANY PROFILES 106

12.1 INTRODUCTION 106
12.2 ABBOTT LABORATORIES, INC. 106
12.3 AGILENT TECHNOLOGIES, INC. 109
12.4 BIOMERIEUX 113
12.5 BIOGENEX LABORATORIES 115
12.6 DANAHER CORPORATION 116
12.7 GE HEALTHCARE 118
12.8 MYRIAD GENETICS, INC. 121
12.9 QIAGEN N.V. 124
12.10 ROCHE DIAGNOSTICS 128
12.11 THERMO FISHER SCIENTIFIC, INC. 133
*Details on Business Overview, Products and Services, Key Strategy, and Recent Developments might not be captured in case of unlisted companies.

LIST OF TABLES

TABLE 1 INCREASING NEED FOR TARGETED TREATMENT IN ONCOLOGY IS PROPELLING THE GLOBAL COMPANION DIAGNOSTICS MARKET 36
TABLE 2 REIMBURSEMENT ISSUES HAMPER GROWTH OF COMPANION DIAGNOSTICS MARKET 38
TABLE 3 ADVANCED TECHNOLOGIES LIKELY TO STIMULATE COMPANION DIAGNOSTICS MARKET GROWTH 40
TABLE 4 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012-2019 ($MILLION) 46
TABLE 5 COMPANION DIAGNOSTICS MARKET SIZE FOR BREAST CANCER, BY GEOGRAPHY,
2012-2019 ($MILLION) 47
TABLE 6 COMPANION DIAGNOSTICS MARKET SIZE FOR LUNG CANCER, BY GEOGRAPHY,
2012-2019 ($MILLION) 48
TABLE 7 COMPANION DIAGNOSTICS MARKET SIZE FOR COLORECTAL CANCER,
BY GEOGRAPHY, 2012-2019 ($MILLION) 49
TABLE 8 COMPANION DIAGNOSTICS MARKET SIZE FOR MELANOMA, BY GEOGRAPHY,
2012-2019 ($MILLION) 50
TABLE 9 COMPANION DIAGNOSTICS MARKET SIZE FOR GASTRIC CANCER, BY GEOGRAPHY, 2012-2019 ($MILLION) 51
TABLE 10 COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER INDICATIONS,
BY GEOGRAPHY, 2012-2019 ($MILLION) 52
TABLE 11 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 54
TABLE 12 COMPANION DIAGNOSTICS MARKET SIZE FOR POLYMERASE CHAIN REACTION,
BY GEOGRAPHY, 2012-2019 ($MILLION) 55
TABLE 13 COMPANION DIAGNOSTICS MARKET SIZE FOR IN-SITU HYBRIDIZATION,
BY GEOGRAPHY, 2012-2019 ($MILLION) 56
TABLE 14 COMPANION DIAGNOSTICS MARKET SIZE FOR IMMUNOHISTOCHEMISTRY,
BY GEOGRAPHY, 2012-2019 ($MILLION) 57
TABLE 15 COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER TECHNOLOGIES,
BY GEOGRAPHY, 2012-2019 ($MILLION) 58
TABLE 16 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012-2019 ($MILLION) 61
TABLE 17 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY GEOGRAPHY, 2012-2019 ($MILLION) 62
TABLE 18 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABS,
BY GEOGRAPHY, 2014-2019 ($MILLION) 65
TABLE 19 GLOBAL COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY GEOGRAPHY, 2014-2019 ($MILLION) 66
TABLE 20 COMPANION DIAGNOSTICS MARKET SIZE, BY GEOGRAPHY,
2012-2019 ($MILLION) 69
TABLE 21 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012-2019 ($MILLION) 72
TABLE 22 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012-2019 ($MILLION) 74
TABLE 23 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012-2019 ($MILLION) 74
TABLE 24 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY APPLICATION, 2012-2019 ($MILLION) 75
TABLE 25 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY APPLICATION, 2012-2019 ($MILLION) 75
TABLE 26 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 76
TABLE 27 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 76
TABLE 28 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 77
TABLE 29 NORTH AMERICA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS, BY TECHNOLOGY, 2012-2019 ($MILLION) 77
TABLE 30 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012-2019 ($MILLION) 80
TABLE 31 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012-2019 ($MILLION) 82
TABLE 32 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012-2019 ($MILLION) 82
TABLE 33 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY APPLICATION, 2012-2019 ($MILLION) 83
TABLE 34 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012-2019 ($MILLION) 83
TABLE 35 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 84
TABLE 36 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 84
TABLE 37 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 85
TABLE 38 EUROPE: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012-2019 ($MILLION) 85
TABLE 39 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012-2019 ($MILLION) 88
TABLE 40 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY END USERS,
2012-2019 ($MILLION) 88
TABLE 41 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012-2019 ($MILLION) 89
TABLE 42 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY APPLICATION, 2012-2019 ($MILLION) 89
TABLE 43 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012-2019 ($MILLION) 90
TABLE 44 ASIA: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 90
TABLE 45 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 91
TABLE 46 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY TECHNOLOGY, 2012-2019 ($MILLION) 91
TABLE 47 ASIA: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012-2019 ($MILLION) 92
TABLE 48 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY APPLICATION,
2012-2019 ($MILLION) 93
TABLE 49 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY END USER,
2012-2019 ($MILLION) 93
TABLE 50 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY APPLICATION, 2012-2019 ($MILLION) 94
TABLE 51 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES,
BY APPLICATION, 2012-2019 ($MILLION) 94
TABLE 52 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY APPLICATION, 2012-2019 ($MILLION) 95
TABLE 53 ROW: COMPANION DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY,
2012-2019 ($MILLION) 95
TABLE 54 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR PHARMACEUTICAL COMPANIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 96
TABLE 55 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR REFERENCE LABORATORIES, BY TECHNOLOGY, 2012-2019 ($MILLION) 96
TABLE 56 ROW: COMPANION DIAGNOSTICS MARKET SIZE FOR OTHER END USERS,
BY TECHNOLOGY, 2012-2019 ($MILLION) 97
TABLE 57 AGREEMENTS, PARTNERSHIPS and COLLABORATIONS, 2011-2014 102
TABLE 58 MERGER AND ACQUISITIONS, 2011-2014 104
TABLE 59 NEW PRODUCT LAUNCHES, 2011-2014 105
TABLE 60 EXPANSION, 2011-2014 105

LIST OF FIGURES

FIGURE 1 RESEARCH METHODOLOGY 18
FIGURE 2 BOTTOM-UP APPROACH 19
FIGURE 3 TOP-DOWN APPROACH 19
FIGURE 4 BREAK DOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 20
FIGURE 5 CDX TECHNOLOGY MARKET SNAPSHOT (2014 VS. 2019): NGS TECHNOLOGY IS EXPECTED TO DRIVE THE GLOBAL COMPANION DIAGNOSTICS MARKET IN THE COMING YEARS 24
FIGURE 6 GLOBAL COMPANION DIAGNOSTICS MARKET, BY APPLICATION, 2014 25
FIGURE 7 GLOBAL COMPANION DIAGNOSTICS MARKET SHARE, 2014 26
FIGURE 8 ATTRACTIVE MARKET OPPORTUNITIES IN THE GLOBAL COMPANION DIAGNOSTICS MARKET 27
FIGURE 9 BREAST CANCER SEGMENT IS EXPECTED TO HOLD THE LARGEST MARKET SHARE IN 2014 28
FIGURE 10 ASIA IS EXPECTED TO WITNESS THE HIGHEST GROWTH IN THE COMING YEARS 29
FIGURE 11 GLOBAL COMPANION DIAGNOSTIC MARKET, BY GEOGRAPHY,
2014 and 2019 ($MILLION) 29
FIGURE 12 GLOBAL COMPANION DIAGNOSTICS TECHNOLOGY MARKET, BY GEOGRAPHY,
2014 ($MILLION) 30
FIGURE 13 ASIAN COMPANION DIAGNOSTICS MARKET IS EXPECTED TO GROW AT A CAGR OF 24.3% DURING THE FORECAST PERIOD 30
FIGURE 14 TECHNOLOGY ADVANCEMENTS PLAY IMPORTANT ROLE IN COMPANION DIAGNOSTICS 32
FIGURE 15 COMPANION DIAGNOSTICS MARKET SEGMENTATION: BY TECHNOLOGY, APPLICATION, and END USER 33
FIGURE 16 COMPANION DIAGNOSTICS GAINED INCREASING DEMAND IN THE ONCOLOGY SEGMENT 34
FIGURE 17 PORTER'S FIVE FORCES ANALYSIS 41
FIGURE 18 STRATEGIC BENCHMARKING: ROCHE AND AGILENT TECHNOLOGIES, INC. LARGELY ADOPTED INORGANIC GROWTH STRATEGIES FOR TECHNOLOGY INTEGRATION AND PRODUCT ENHANCEMENT 43
FIGURE 19 THE COMPANION DIAGNOSTICS APPLICATIONS MARKET WILL BE DRIVEN BY THE GROWTH IN INCIDENCE and PREVALENCE OF BREAST AND LUNG CANCER 45
FIGURE 20 LUNG CANCER IS EXPECTED TO HAVE A LARGER MARKET SHARE IN THE FUTURE 46
FIGURE 21 PHARMACEUTICAL FIRMS DOMINATE END-USER MARKET, REFERENCE LABS SHOW HIGHEST GROWTH 60
FIGURE 22 ADOPTION OF COMPANION DIAGNOSTICS GROWING SIGNIFICANTLY AMONG PHARMACEUTICAL COMPANIES, REFERENCE LABORATORIES 60
FIGURE 23 PHARMACEUTICAL COMPANIES IN NORTH AMERICA: ARE THE MAJOR END USERS OF COMPANION DIAGNOSTICS 63
FIGURE 24 REFERENCE LABORATORIES IN NORTH AMERICA ARE CONSIDEREDTO BE THE SECOND LARGEST END USERS OF COMPANION DIAGNOSTICS 64
FIGURE 25 COMPANION DIAGNOSTICS TESTS ARE GAINING IMPORTANCE IN ACADEMIC MEDICAL CENTERS AND HOSPITALS DUE TO THEIR GROWTH POTENTIAL 66
FIGURE 26 ASIA IS EXPECTED TO BE THE FASTEST-GROWING MARKET FOR COMPANION DIAGNOSTICS 69
FIGURE 27 RISING PREVALENCE OF LIFE-THREATENING DISEASES TO DRIVE MARKET GROWTH IN NORTH AMERICA 71
FIGURE 28 EUROPE COMMANDS ONE-THIRD OF THE GLOBAL COMPANION DIAGNOSTICS MARKET 79
FIGURE 29 COMPANIES ADOPTED COLLABORATIONS/PARTNERSHIPS/AGREEMENTS AS THE KEY GROWTH STRATEGY OVER THE LAST THREE YEARS 98
FIGURE 30 TOP 5 PLAYERS OCCUPY 86% SHARE OF COMPANION DIAGNOSTICS MARKET (2013) 99
FIGURE 31 BATTLE FOR MARKET SHARE: PARTNERSHIPS, COLLABORATIONS, AGREEMENTS WERE PREFERRED STRATEGIES 101
FIGURE 32 ABBOTT LABORATORIES, INC.: BUSINESS OVERVIEW 106
FIGURE 33 AGILENT TECHNOLOGIES, INC.: BUSINESS OVERVIEW 109
FIGURE 34 SWOT ANALYSIS 112
FIGURE 35 BIOMERIUX : BUSINESS OVERVIEW 113
FIGURE 36 DANAHER CORPORATION : BUSINESS OVERVIEW 116
FIGURE 37 GE HEALTHCARE : BUSINESS OVERVIEW 118
FIGURE 38 MYRIAD GENETICS : BUSINESS OVERVIEW 121
FIGURE 39 QIAGEN N.V. : BUSINESS OVERVIEW 124
FIGURE 40 SWOT ANALYSIS 127
FIGURE 41 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW 128
FIGURE 42 SWOT ANALYSIS 132
FIGURE 43 THERMO FISHER SCIENTIFIC INC. : BUSINESS OVERVIEW 133
FIGURE 44 SWOT ANALYSIS 135

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics 2020: Supplier Shares and Strategies, Country Segment Forecasts, Technology Trends, Emerging Opportunities--Tumor Markers, Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • October 2016
  • by Venture Planning Group

Complete report $34,750.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

Cancer Diagnostics Market Segmentation Analysis: Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • $ 21100
  • Industry report
  • August 2016
  • by Venture Planning Group

Complete report $34,500.  DataPack (test volumes, sales forecasts, supplier shares) $21,100.  The report is available by country, section, market segment, and can be custom-tailored to your specific ...

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

Europe Tumor Marker Diagnostic Testing Market: Future Horizons and Growth Strategies--Instrument and Reagents Supplier Shares, Country Segment Forecasts, Competitive Intelligence, Opportunities

  • $ 12800
  • Industry report
  • August 2016
  • by Venture Planning Group

This unique report provides information not available from any other published source, including volume, sales, and leading supplier shares by test. This comprehensive five-country report identifies and ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.